Latest / The Dokkcast / The Truth About GLP-1 Weight Loss: Nutrition, Muscle Loss & Ozempic with Dietitian Marcela Fiuza
Transcript
- 0:08Nara: Welcome everybody to our number eight in our Dokkast series. And I'm joined today by Marcela Fiuza, who's a registered, dietitian. And it's one in a series that we're doing with Marcela around nutrition, particularly focusing on women in their forties. But actually today we're going to be discussing GLP-1s. But tell us a bit about yourself, Marcela.
- 0:26Marcela: Thank you. Thank you for having me again. Absolute pleasure. Yeah. So I'm a rest of dietitian.
- 0:32My experience is I've been I've worked in the NHS for many, many years, and for the past six years, I've been working in private practice. Mhmm. And my focus is on metabolic health. And I've got a special interest in women's health as well. But a lot of the work I do on a day to day basis is related to weight management with and without medication, but over the past few years,
- 0:56Nara: kind of GLP-one has been, a big a big part of my practice. Yes. Is. And it's probably not too much of a stretch to say that GLP-1s have been transformational. Yeah.
- 1:08Both individually as well as at population level. Absolutely. So tell us what it is. What is it? What does it stand for?
- 1:16What does it do?
- 1:17Marcela: Right. So, it's, you know, we refer to old GLP-1s as kind of the weight loss medication. So there are other names as well that you might see in the media, but that's what kind of most people refer to those, that class of medication. But GLP-one is actually kind of a peptide that we naturally produce in our body. So it's produced in the gut in response to when we eat food.
- 1:44Mhmm. So and what it does, it signals satiety to the brain, so it tells the brain that we've had enough. Mhmm. And it also acts on the pancreas to release insulin, so it helps with blood sugar control. And it also slows down gastric emptying.
- 2:00So the overall result is that we feel full and we stop eating. Or we eat less. Fuller quicker. Exactly. Mhmm.
- 2:09The natural GLP-one that we produce, it's it lasts for a few minutes in the blood. So it's very, very short lived. Quick release. Quick release, quick effect, that's it.
- 2:21Nara: Quick loss. It's gone.
- 2:22Marcela: Yes. So the medications that we have available right now, so they are GLP-one receptor agonists. So they are engineered versions of GLP-one Mhmm. That they bind to the GLP-one receptors in the body, but they last for a lot longer and they have this amplified response. Mhmm.
- 2:42So they are, well, at the moment, the two mostly commonly use, they are injected once a week. Mhmm. And they last for days, usually for about a week. It starts to fade away towards the end of the week. And they have this much bigger response.
- 2:59So what they do, they really reduce appetite. A lot of people will report this kind of reduced food noise. They think a lot less about food. They significantly reduce their kind of food intake. And they also do those things, same things that the natural GLP-one does in terms of helping to improve blood sugar control and slowing down gastric emptying as well.
- 3:24Nara: Fantastic. So it's actually mimicking a natural hormone that we'd have. Yeah. And the combined effect is multifaceted. So it acts on the brain, acts on the gut, on the stomach, stomach emptying, and also gives you greater greater shot of insulin so you can process the food that you've that you've just eaten.
- 3:41Marcela: Yes. Exactly.
- 3:42Nara: And there's a number of companies that make it, obviously. There's different types that it comes as. They're injectable now.
- 3:49Marcela: There's a
- 3:49Nara: shift to oral?
- 3:50Marcela: There is. There yes. There will be. And I think, you know, there are so many different, drugs coming, you know, in pipeline developing at the moment. I think at the moment in The UK, the most commonly used are semaglutide, which, you know, for the use for weight management, it's the brand name is called Wegovy.
- 4:13It's also known as Ozempic, but that's the brand name for the one used to manage type two diabetes. And we also have tirzepatide, which the brand name is Mounjaro. So those are the most commonly ones used in The UK, and they work slightly different. So, Wegovy semaglutide is, GLP-one receptor agonist, so it acts on that one pathway. And the tirzepatide, the Mounjaro, is a dual agonist.
- 4:44So in addition to, binding to GLP-one receptors, it also acts on an additional pathway, binds to the GIP receptors. Mhmm. So it just seems to have, slightly stronger effect. So on the trial data from both, different drugs, so with the semaglutide, people tended to achieve around 16% weight loss. Mhmm.
- 5:08And with the Mounjaro, with the dual agonist, the weight loss was slightly above that, so it was between 20 to 22%. Mhmm. But as I mentioned, there are loads more coming up. Yes. And I think the latest published kind of results from one of the drugs that are currently on trial for safety and effectiveness, I think it's a phase three trial, is a triple agonist.
- 5:34So in addition to binding to GLP-one and GIP, it also binds to glucagon receptors. And that seems to increase the effect on weight loss, and I think it achieved somewhere between 2428% weight loss.
- 5:48Nara: It's very high.
- 5:48Marcela: It's healed. So as you rightly said, it's completely changing, revolutionizing obesity management because this level of weight loss, previously, we had only seen with bariatric surgery, which is a very invasive treatment.
- 6:04Nara: Yeah. That's a very heavy surgery, obviously, to and bariatric surgery essentially is what's sometimes known as gastric sleeve
- 6:11Marcela: Yeah. Yeah. There's different types. And they are, very effective for for long term weight management. But the fact that there we are seeing similar results with something that's a lot less invasive.
- 6:26Nara: Mhmm.
- 6:26Marcela: It it is revolutionizing. Yeah.
- 6:29Nara: Who would it be the right treatment for? Obviously in obesity or type two diabetes management, but, what are the criteria for someone to go on that? And importantly, obviously now it's shifting quite a lot into primary care, but who would be prescribing this?
- 6:44Marcela: Yeah, so, okay, there are a few different aspects there actually. So there are the trials that have been done and what these drugs are actually licensed for. Mhmm. And there is what you're able to access via the NHS. So, you know, which is pretty much dependent dependent on funding.
- 7:03Mhmm. And what you're able to access privately.
- 7:07Nara: Yep.
- 7:08Marcela: Which is a whole different story. Yes. So with the trials, so these drugs, when they were studied, they were studied in mostly individuals that live with obesity. So with a BMI above thirty.
- 7:23Nara: BMI being your body mass index.
- 7:25Marcela: Body mass index, yeah. We all know body mass index is not a perfect measure, but it's an indication. And so these people are living with obesity and individuals also, they were overweight, so with a BMI above, usually above twenty seven in these studies. And they already had, some consequences of excess adiposity. So it could be type two diabetes or cardiovascular disease, for example.
- 7:53So the benefit from these medications, with that particular population group was very obvious. Yeah. The reduction of weight and the improvements in health were significant to justify the risk because that's something, you know, any medication that you take, there needs to be that assessment of risk benefit. And so we know that for that population group, benefits are greater than the risks. Yep.
- 8:23Yep. What we don't know yet is the benefit for people that fall outside So that population at the moment, yeah, so that's the kind of trial data that we've got. And then via the NHS, the the criteria for for getting prescription, I think, is very, very tight, and it depends on the area that you are as well.
- 8:48Nara: This is for The UK.
- 8:49Marcela: For The UK.
- 8:50Nara: In different parts of the world. Yeah. Yes. Funding stream.
- 8:52Marcela: Yeah. Yeah. Which, you know, it seems unfair, but it's where we are at the moment, and and hopefully things things will change. But unless you fall you you fall into this very tight criteria, it's unlikely you'll be able to access by the NHS. And actually, like ninety five percent of people in The UK access this medication privately.
- 9:13Privately. So people do have
- 9:14Nara: to pay interest.
- 9:15Marcela: Okay. Yeah. Yeah. But on the NICE guidelines is that, yeah, you you know, need to be kind of living with obesity Yep. Or overweight plus one or more kind
- 9:28Nara: of comorbidities. Conditions that are caused by obesity such as cardiovascular risk, type two diabetes.
- 9:33Marcela: Yes, exactly. And it's slowly kind of as we understand, get to understand more about the kind of the benefits and the side effects and safety data, those indications might be changing. So cardiovascular disease is something that's been kind of added on. So there is quite strong evidence of the benefits of semaglutide in that area. And we increasingly kind of becoming aware and understanding more about the benefits in potentially things like osteoarthritis and fatty liver disease and sleep apnea, for example.
- 10:08Nara: A lot of the other things that come come as part and parcel of living with Yeah. Yes. Yes, exactly. So let's talk about what happens nutritionally speaking, when you're in GLP-one and that's going to lead me on to what we can do about it. But yeah, what happens to your body other than obviously with some of the things that you've mentioned about slower gastric emptying, greater insulin release, Nutritionally, what's going on?
- 10:30How how is that changing what's going on inside your body and how is GLP-1s changing your behavior as a result?
- 10:37Marcela: Yeah. So that's a that's a really interesting question because there are things that the job ones will do and there are things they doesn't do. Okay. Yeah. So one thing that it does is to reduce your feed intake.
- 10:53And that can be huge. So feed intake can reduce like by 40% Mhmm. Which is massive. What it doesn't do is change the types of food that you eat. Mhmm.
- 11:06Nara: Yeah. Although That's a really good point. Yeah. So what you're eating
- 11:11Marcela: and the It's variety up
- 11:12Nara: to you. That's your choice. Exactly. So if you're making poor food choices before, those poor food choices might still be there except just 30% less of them.
- 11:21Marcela: Yes. Exactly. 30 or 40% less And poor is
- 11:24Nara: not a judgment call. It's just to say nutritionally optimized.
- 11:27Marcela: Nutritionally. So a diet that maybe is very high in ultra processed foods, very nutrient poor, you might still be having that same type of diet but 40% less, you still lose the weight, but it doesn't mean that nutritionally, it's a it's you know, it's It's being right thing. It's the right thing for you to do. So I think that's a very kind of important distinction
- 11:50Nara: Mhmm. Mhmm.
- 11:51Marcela: Of what happens. And it's and that's where the risks lie for me, like as a dietitian, I just I feel that it's such an important aspect that doesn't get talked about enough. And while people are starting to talk a little bit more about it and about the wraparound care. Let's
- 12:13Nara: talk about that now. So what does a good GLP-one diet look like? How would you need to adjust it if you're on the GLP-1s as well?
- 12:23Marcela: Yeah. So again, it's very individualized. We'll talk a bit about it, but it's very individualized and it's just important to highlight the importance of the wraparound care around this. And if someone is accessing the medication via the NHS, it's more likely to have a structured kind of program around it where you might be have access to a dietitian or some kind of behavioral coach and input. Whereas we know that ninety ninety five percent of people are accessing it privately, and then the the level of wraparound care that you Can be highly variable.
- 12:55It's very variable. And it's variable to the point that, you know, like, I I work with, a group of doctors and they offer amazing wraparound care to the patients but you might be able to get a prescription online and the wraparound care that you get
- 13:12Nara: is No, a list are of accessing it online, of course, not realizing that actually you can't just do that and not look after the rest of your nutritional intake.
- 13:20Marcela: Absolutely. And you know, it might be that the nutritional guidance that you're getting is a leaflet saying to eat less, exercise more. And we know that that doesn't work because if it did work, we wouldn't be here in post place. Yes, exactly. And the other thing that is really important to consider as well is that if the medication is being used as as it should for people that are living with overweight and obesity, people that are living with obesity, are already at kind of a high initial risk.
- 13:57Mhmm. So because of, you know, a range of different factors, dietary patterns, we know that people with obesity are more likely to have nutrient deficiency, for example.
- 14:07Nara: So you're starting from a suboptimal position, nutritionally
- 14:10Marcela: speaking Exactly, before you even started the medication and then suddenly you're cutting your intake by 40%. And if you don't change anything in your diet, then that that's not
- 14:20Nara: So in the truth, would it be fair to say that starting GRP one should be a pivot event where your nutritional profile and behavior needs to change?
- 14:34Marcela: Absolutely. And that is I feel that kind of diet and exercise have to be part of that prescription because I think just the prescription without nutrition intervention, you know, at its best, it's just a missed opportunity. And I think the worst is just like a clinical risk
- 14:55Nara: because you might be. What does that intervention Right. Like at its
- 15:01Marcela: So we know that intake will be significantly reduced. It's slowly shifting from towards more kind of nutrient dense meals. Right? So a lot of people really don't feel that hungry, especially when they are adjusting or increasing doses. So often what what people say that they find helpful is rather than having like, for example, a few meals a day and snacks.
- 15:28It's having a little bit more structure and having smaller meals through the day and smaller meals, and it might be, like, eating occasions, like, five or six eating occasions through the day.
- 15:39Nara: The three school meals.
- 15:40Marcela: Yeah. Not to say that before people were eating three meals because often that that is not the case.
- 15:46Nara: Mhmm.
- 15:46Marcela: But establishing some kind of structure. So the way I see with the GLP-1s and which is often what people will say to me in clinic is that it's things that you knew you had to do before and you couldn't do it, suddenly you're able to do it. It's possible. It's possible. So the way I see it is this window of opportunity where- You must grab.
- 16:09You must grab that suddenly those changes, eating regularly, balancing your meals properly, eating enough fiber, eating enough protein, eating healthy fats, exercising, all those things that before felt really, really, really difficult to achieve. You've got
- 16:26Nara: an opportunity now.
- 16:27Marcela: Possible and you've got an opportunity. And it's up to kind of the prescribers and the kind of the services behind it to offer this wraparound care.
- 16:40Nara: It goes back to that holistic approach, doesn't it? To think that's a being because actually, you know, and we're gonna come to that in a second, at some point you're going to come off them. So what happens then? And unless you've actually used that window of opportunity to actually pivot to a good nutritional start, then then that was gonna be very difficult. So do you give any sort of so obviously structure is one of the advice that you give.
- 17:03Having that again, we go back to intentionality about it to say, look, this is what I'm going to eat. This is what my meal plans look like. Do you give them any absolute advice in terms of, protein intake or or fiber intake or any of those? Any any of those sort of guidelines? Is that something that you talk about with them?
- 17:24Marcela: Or Yeah. Protein protein intake.
- 17:30Nara: I
- 17:31Marcela: think that's mine. I put mine on. Fine. Ah.
- 17:34Nara: Yeah. That's fine. Sorry. I can give it a letter. Yeah.
- 17:36Sorry. Yeah. So we'll go back to yep. We'll be back. Okay.
- 17:40So so, yeah, so I'll I'll I'll queue you in. So, on that particular question, I'm I'm I'm looking for, if there's anything particular they should be doing.
- 17:51Marcela: Yeah. Terms of protein.
- 17:52Nara: Yeah. Instead of protein or fiber or anything like that, is is there anything that they need to, and to some degree, how is that advice different from from any other advice that you would give?
- 18:01Marcela: Yeah. Mhmm. Yeah. So in terms of protein, protein is something that significantly drops when people start on this medication. Mhmm.
- 18:09So, you know, I'm saying that from kind of clinical experience, the actual evidence around diet intake for people on GLP-one is lagging behind where we are in terms of the drug development. There are some studies that are available that show that, you know, there's often insufficient intake in terms of protein, insufficient intakes for a range of vitamins and minerals. So things like iron, zinc, magnesium, vitamin b twelve, vitamin c, vitamin d is a very common one, and many people living with obesity, have vitamin d deficiency already. So but protein in particular is something that tends to drop very quickly. Protein is very satiating as a as a macronutrient, and it requires more effort.
- 18:58It's more expensive. It requires a little bit more planning, but it's something that is extremely important. Mhmm. Mhmm. So I focus a lot on the, you know, on how much protein you should be having a day in combination with resistant exercise.
- 19:16And the reason for that, it's because with weight loss, so with any weight loss, you lose fat mass, but you lose lean body mass as well, including muscle mass.
- 19:26Nara: So that's really important.
- 19:27Marcela: Right? That's really important because we want to be able to lose the fat mass and preserve the muscle mass as much as possible. You're not you're not able to entirely prevent it, but you can minimize it. Yeah. And then with an with a goal of kind of optimizing lean body mass.
- 19:44Nara: And that's one of the sort of, criticisms slash risks that has come with the GLP-one therapies is that, yes, there is spectacular weight loss. Yeah. But quite a bit of that seems to be muscle mass loss. Yeah. And there was some evidence recently that the muscle mass loss may even precede the fat loss.
- 20:03So when we're going into any GLP-one treatment, we need to think about, how to lose the weight we want, I. E. The adipose, the fat tissue, how do we keep, the weight that we do want, which is the muscle.
- 20:17Marcela: Absolutely. And the reason for that is that muscle mass is extremely important. It's a really kind of metabolically active tissue. So it's very important for our mental
- 20:28Nara: health. Not just for strength.
- 20:29Marcela: It's not just for strength, but it's also really important for strength. And we know that kind of sarcopenia, which is age related loss of, of muscle mass and and strength, is associated with poor health outcomes, with, fractures, with falls, with mortality. So it's something that we really want to preserve in the long term. So the the goal with this with this drugs and with weight management shouldn't simply be reduced size, it should be improved health. And retaining the muscle is something that that is part of that.
- 21:02It's really important.
- 21:03Nara: And people don't always appreciate that muscle is an active organ, if you will.
- 21:07Marcela: It's it's
- 21:08Nara: not just for strength.
- 21:09Marcela: No. It's important for your blood sugar management, for cholesterol management. It's important for all for all sorts of things. So, yeah, and and and we know from data from from the research of these drugs that it it varies between studies, but anywhere between twenty to forty percent of the weight loss can come from lean mass.
- 21:29Nara: From lean mass.
- 21:30Marcela: And
- 21:30Nara: that's quite high.
- 21:31Marcela: That is And it's not to put people off the medication, which I think can be life changing for some people when used appropriately. But it's just to say that that can be addressed and it can be minimized and
- 21:47Nara: We can actually look at that.
- 21:49Marcela: We can look
- 21:49Nara: at can address it. Exactly. We can prevent it.
- 21:52Marcela: Exactly. But it does require planning and intention to do that. Because once your appetite goes down, the protein will be compromised at a time that your protein
- 22:06Nara: Needs to,
- 22:06Marcela: if anything, increase. Exactly. Because like overall protein recommendations at the moment, they are zero point eight grams per kilogram per day, which most experts and scientists will agree that is too low, and definitely too low for someone that is on the GLP-one, we are aiming more for somewhere between one point two to one point six grams per kilo per day.
- 22:29Nara: So that's quite a bit higher than the baseline requirement.
- 22:32Marcela: It is. It is quite a bit higher. What Yeah. And does that what
- 22:36Nara: does that look like in real life?
- 22:37Marcela: Well
- 22:38Nara: What what is that for, say, you know, let's call it seventy kilo. Normally, all the studies are on seventy five kilo men, but we're we're gonna glaze past that and just say, does that look like on average?
- 22:49Marcela: So let's just, you know, to make it really easy, let's look at 100 of protein per day. Okay? It's not that easy to achieve that. So I'll give you an example of what is not uncommon for me to see in clinic for a woman in her mid forties, for example, going to a perimenopause, menopause, and on a GLP-one medication, okay? And probably thinking, yeah, no, I eat pretty well overall.
- 23:16And it's not to say that this particular woman, they don't. They do. But it's that perception that, well, I'm having a bit of protein with every most meals. I'm probably okay. But for example, if breakfast is a couple of slice of toast or some cereal with milk, you might be getting, I don't know, a push depending on what you're adding to your toast.
- 23:41A real push, you might be getting 10 grams of protein.
- 23:44Nara: Nothing.
- 23:44Marcela: Not much. And then and and breakfast does tend to be the lowest protein meal of the day for most people. For And most then it comes lunchtime. Yeah. You're picking something up like around work time and it might be a sandwich.
- 23:58Mhmm. Maybe a sandwich and a salad if I'm being very good. Yeah. And so a sandwich, there might be some protein there. There might be very small amount.
- 24:09But okay. Let's be generous and say that you get you're managing to get 20 grams of protein for your lunch.
- 24:15Nara: So we're up
- 24:15Marcela: to 30. It's unlikely with your sandwich, to be perfectly honest. But, yeah. Okay. You're getting 20 grams of protein, so up to 30.
- 24:23And then you have a few snacks in the afternoon. Again, you're being really good. You're having handful of nuts maybe, and a piece of fruit. Yeah. So you get a bit more protein there depending on how many nuts you're having, how much is your snack.
- 24:37But let's say you're getting five grams of nuts, of of protein in the afternoon. Mhmm.
- 24:41Nara: So we're up to the dizzying heights of thirty five?
- 24:43Marcela: Thirty five. Exactly. And then comes nighttime and you're gonna have a proper meal, you have a
- 24:49Nara: Be generous, call it a chicken breast or a steak.
- 24:51Marcela: Exactly. A chicken breast or a salmon fillet or something, so a good size and you're getting about 30 grams of protein there and you're still having like, I don't know, maybe some rice and some salad, maybe there are some seeds and some chickpeas on that salad or something like that. So let's say you got 35 grams of protein with
- 25:13Nara: that dinner. So you're kind of up to 70 now, which is
- 25:15Marcela: which is the max
- 25:16Nara: that you've achieved being very generous overall.
- 25:18Marcela: Yeah. And and can even say that, you know, you you picked on a few different things. You had a bit of cheese there. Maybe you had a bit bit of yogurt. So even if you feel that, okay, I've had a regular meal.
- 25:31I've added quite a bit of protein. I had protein with every meal. Still haven't reached that. You still haven't met it. And I don't want people to get obsessed with numbers, but I think it's just having that awareness that it's harder it's harder than you think.
- 25:46And when you're on the medication that cuts your appetite down by 30 to 40%, it's harder.
- 25:53Nara: So it's gonna be that
- 25:54Marcela: much less than that. Yeah. It's not uncommon, like, once I start talking to someone that has recently started medication, okay, so what's your diet like at the moment? Oh, I'll have, I can't really eat in the morning, I'm not feeling hungry, I'll have a cappuccino mid morning and then I'm not hungry again until mid afternoon. She will fall
- 26:14Nara: in behind massively as the day goes on.
- 26:16Marcela: Massively, And that's a really
- 26:18Nara: good segue into saying what are the risks Yeah. With with GLP-1s Yeah.
- 26:23Marcela: So the risks, so we've touched on the protein and then the muscle mass, so that is the kind of main one. But then there are the risks of nutritional deficiencies as well. So as I said, the data from kind of the research is lacking a little bit, but something that we already see in clinic is that people are at risk of nutritional deficiencies. So the most common ones are kind of like iron, vitamin d, vitamin b twelve. Yeah.
- 26:54And it might not be that easy to identify. So, you know, if you are a healthcare professional and you are prescribing those drugs, do keep those things in mind and symptoms like excessive tiredness. I think tiredness is very common when people are taking these medications because if you're losing weight, like at fast race
- 27:16Nara: a lot going on in your body at
- 27:17Marcela: that Exactly. It causes tiredness. So people might not necessarily think, oh, it's a nutrient deficiency, but it's really important to check. It's really important to check ferritin levels. It's it's because you're not holistic.
- 27:28Exactly. And you might not be like full to have full blown anemia, but your ferritin levels might be quite low and might require a little bit of attention. Mhmm. Vitamin d levels. So things like hair loss.
- 27:43Hair loss is common as well, and it's not always because of nutrient deficiencies. It's because of the weight loss itself. But excessive hair loss does require a little bit of investigation. Yeah. Excessive tiredness, muscle weakness, flaky skin.
- 28:01There are there are deficiencies Systems
- 28:03Nara: changes on that.
- 28:04Marcela: Exactly. So there's deficiencies that we were not seeing so much anymore that now they're becoming a little bit more common in that population group.
- 28:15Nara: So we need to think about that as well. We have
- 28:16Marcela: to think about So not
- 28:17Nara: just about weight, about the diet, but also specific aspects of of the of the whole three sixty nutritional profile of someone.
- 28:24Marcela: Absolutely. Yeah. Absolutely. And and because your your your eating, your kind of your appetite budget is so reduced that whenever you're spend it wisely. Something You have to spend it wisely whenever you're eating
- 28:38Nara: something budget.
- 28:39Marcela: Yeah. It's an opportunity to to nourish yourself and and you can't waste it.
- 28:44Nara: It's almost like the flip side of the food noise, isn't it? So you've got the food noise goes down, so therefore you now need to spend that currency, if you will, what you're eating really, really wisely.
- 28:55Marcela: Really wisely because your opportunities the opportunities that you have to nourish your body, it's it's very reduced.
- 29:01Nara: Yeah. I like those two because they're in a in a sort of it needs to be on an equipoise around, you know, food noise down, appetite, budgeting up. So and if you could reflect a little on how this in particular changes for women around their forties, perhaps perimenopausal, perhaps not, but definitely how the GLP and the muscle loss is a particularly pertinent feature for women.
- 29:26Marcela: Yeah. So that that that's really interesting because women in their forties, so perimenopausal, menopausal women often experience weight gain and this kind of fat redistribution, and we've talked about that in our other other podcast. So it has been a group that has been really interested in this medication, and it's where the medication can be really useful when used correctly. Mhmm. But we know, for example, that during perimenopause and menopause, muscle mass naturally declines.
- 30:03The other important aspect is bone density as well. Bone density naturally declines, and those are two things that can be affected by the medication. So it just requires that extra level of vigilance. Mhmm. And you have to be extra careful in terms of the diet.
- 30:18Make sure you're having enough vitamin d, enough calcium, enough protein to make sure that you're not just reducing your size, but that you're improving your health. Mhmm. So there's some really extra important considerations for number of pillars women in for women midlife. Absolutely. So if
- 30:34Nara: have your GLP-one, you absolutely have to think about nutritional intake, You having a plan for must actually assess and your doctor should do this anyway or nutritionist or dietitian but actually get a really complete profile of the minerals and vitamins.
- 30:48Marcela: Yeah, not everybody is going to get that.
- 30:51Nara: But it would
- 30:52Marcela: be optimal? It would definitely be optimal. Not everybody will get it but I think definitely it, you know, depending on the side effects that you're having, those things that we mentioned, the excessive tiredness, and it's definitely worth
- 31:07Nara: Worth looking at.
- 31:08Marcela: Yeah. And the exercise, resistant exercise. So that's extremely important. The protein, the additional protein in itself, it's not going to Yeah. To anything.
- 31:18So it has to be in combination with the resistance exercise.
- 31:21Nara: And just to summarize, the things that are worth checking is your ferritin, which is your iron stores because that will that will that will be an important marker before any sign of anemia, your b twelve, your zinc, your magnesium, as well as anything cholesterol.
- 31:34Marcela: B twelve, I think is extremely important. Yeah. Okay.
- 31:38Nara: Fantastic. And then of course, hopefully you're not on this medication forever, if you can optimize it. What happens when you stop? Because we're now seeing obviously, you know, a few years of that. By the way, really interesting thing happening to sort of the hospitality sector as a result of these GLP-1s because people are going going out less.
- 32:00Yeah. They do go out, they're drinking way less. Yeah.
- 32:04Marcela: It's just really interesting how the medication works in the brain to not only not only reduce food intake, but reducing kind of cravings overall. Yeah. Yeah. And people just don't feel like drinking.
- 32:16Nara: Yeah. The alco yeah. Yeah. So so so something very interesting is happening over there on the on the consumer market. Very interesting.
- 32:22Drinks, with obviously 0%, alcoholic beverages, you know, definitely having a moment. But you hope to come off it. Yeah. What happens when you come off it, good and bad?
- 32:35Marcela: Yeah. So I think before I go into that, I think it's probably just really important to stress that obesity is a chronic disease.
- 32:46Nara: Mhmm.
- 32:46Marcela: And like many other chronic diseases, it may require medication that is there for the long term. So not everyone will come off the medication, but a lot of people will. And I think what we have data for at the moment is that most people are accessing it privately, and the kind of retention rates, so most people will come off Mhmm. With it. I I don't I I don't remember the exact numbers, but it's about seventy or seventy five percent will come off within eighteen months.
- 33:16So we do know that quite a bit
- 33:17Nara: short Yeah. They're almost using it in a way to try and get over the huge hurdle of initiating and sustaining a prolonged and significant weight loss. Which GLP-1s will do really well.
- 33:31Marcela: Yeah. And I think there will be a lot of other drugs coming in the pipeline and hopefully there could be something that, you know, potentially in a pill format that might be able to help with that phase of weight maintenance. Because what we know with the job you want is that they work extremely well for when you're taking them. Mhmm. The moment you stop taking it, the appetite will return.
- 33:55Mhmm. Because we've got this set point for the weight that our biology will protect. And while you're taking a GLP-one, that we are kind bypassing. It's not even some assay changes, but we are bypassing our natural biology. Yeah.
- 34:14So the moment you stop taking it, your appetite will return. And it's really individual, it's really variable, and I have, I think the data shows that people will gain the weight back. Back. Most of the weight. And most people will regain a lot of the weight back.
- 34:32Do
- 34:33Nara: we know over what period of time?
- 34:37Marcela: I think I think the data is for in about eighteen Mhmm. Because they look at the weight loss over a period of eighteen months as well. Mhmm. But what I see in in in clinic is it's really dependent on your starting point. So it depends on the level of weight loss that you needed to achieve to start with.
- 34:59So if you're people that had less weight to lose, so maybe in the overweight rather than in the obesity category, have significantly changed kind of lifestyle, eating habits, they are more likely to be able to achieve or to minimize that weight gain after.
- 35:16Nara: Which completely goes to the point of this window of opportunity which must not be lost.
- 35:22Marcela: Absolutely. Entirely. It's it's so important. It's so important. And every prescription should come with the prescription for diet and exercise.
- 35:33Nara: I think that point.
- 35:34Marcela: I think it's absolutely non negotiable.
- 35:36Nara: Yeah. Because actually, if you if you then say this is your moment when you can affect all those changes that you wanted to affect in your life in terms of the type of food you eat, the frequency with which you eat,
- 35:49Marcela: of It's course now.
- 35:50Nara: Yeah. Now is the moment because actually as and when you come off that, you can then completely carry those habits on.
- 35:57Marcela: Yeah. Yeah. Because we know it takes time to form a habit. So, you know, there is no point as well in taking the medication for a month. Yeah.
- 36:05If you're only taking it for a month, you're probably not using it for the right reasons. You're probably using it for cosmetic reasons, which is not what it's licensed for, and we don't have data and like for efficacy and safety for that. So it shouldn't be used for that very kind of short term. But the other the other point as well about kind of using it for a point for a while and then stopping it without making those modifications, something that we still don't have that data, but something that worries me is that people might end up like, it might not happen, but in my mind, I worry that people might end up worse off than they were when they started weight. So for example, you start, you've got this certain amount of muscle mass and you're living with overweight or obesity, you lose significant weight, 40% of that weight loss is muscle mass.
- 36:58And then once you regain that weight, you're not going to regain muscle. It's very difficult to gain muscle. So you're unlikely to regain that weight in muscle. You're much more likely to regain that weight in fat tissue.
- 37:10Nara: So you might actually be worse off than what you started
- 37:12Marcela: off with. Exactly. So you might end up with psychopenic obesity, which is excess fat mass and insufficient muscle mass, which metabolically is a lot more dangerous Than where you started. Than where you started. So,
- 37:27Nara: yeah, it it just seemed important. Intentionality and a wraparound care for people at the time of starting, which kind of goes against giving anyone the advice to say, oh, good. Just get it online. That will be it. That will be fine without it dovetailing into really good, effective nutritional advice.
- 37:48Marcela: Yeah. And I and I think there are different kind of online platforms that that do offer that do offer that wraparound
- 37:54Nara: So look for that.
- 37:55Marcela: So look for that. Yes, exactly. Look, ask for the wraparound care. Yeah. You know, if you can, because it's a missed opportunity.
- 38:04Otherwise. Otherwise, definitely.
- 38:07Nara: So yeah. So that that that kind of brings us all very well into the if you had to sort of give one advice to people starting on GLP ones or looking to start on GLP ones, it sounds like that would absolutely focus on the fact that this is this is a road and this is a journey. Yeah. Don't look at it as a snapshot in time. No.
- 38:26What's your what's your lead advice to them to think about? You're you're thinking about starting GLP when you've been advised perhaps, so this is the way forward for you. What's the one piece of advice to them to try and bring this all together?
- 38:39Marcela: Wow. Very good question. So difficult to summarize the one piece of advice. There are so many. I think that, you know, focusing on a nutrient dense diet is extremely important.
- 38:58And one aspect of it that I think is absolutely crucial, not in isolation, that's the difficulty, it's it's picking things in isolation, everything is so important. But one aspect of it, the adequate protein intake and the resistant exercise Mhmm. Is extremely important. Mhmm.
- 39:17Nara: So go into it having your exercise regime worked out. Go into it having your nutritional regime worked out. Absolutely. And have a real plan, both what you're gonna do before, during, and after GLP-1starting Yes.
- 39:31Marcela: It's it's very hard to do it on your own. So choose a provider that offers that wraparound care.
- 39:40Nara: Mhmm. Ask around. Exactly. And
- 39:42Marcela: it might not be it might not be a registered dietitian, but there are many kind of providers that will have nutrition cultures that have been trained to give that advice. So do ask around, shop around and see and see what's available. What's available. Because it's very, very important.
- 39:59Nara: Do you have a view on microdosing of GLP-1s?
- 40:02Marcela: Oh, do I. I think you'll probably know my view on microdosing. Well, I think, well, first of all, I think people use the word microdosing meaning different things. So I've heard people saying that they were microdosing, meaning that they're just using the lowest licensed dose, which is not dosing. It's not micro That's just dosing.
- 40:27Dosing. That's just dosing. And then there are people, there are a lot of people that, just do their whole thing with them at least, I think will go completely off piste. And I think that's really dangerous. Yeah, but don't do Don't do that because that's not how the drugs have been studied, trialled for efficacy, for safety.
- 40:54So don't do that and ask yourself what's the point of the microdosing? Is it to maintain weight? Is it to lose just a couple of kilos? If it's just for losing a couple of kilos, it might be that there are ways around it without the medication to start with.
- 41:12Nara: That may not be the best one.
- 41:13Marcela: Or if you if if yeah. I think follow, your doctor's kind of advice on what's the best to do in terms of, you know, are you stopping the medication completely or you are kind of, bringing the dose down to the kind of minimum amount. It might be that there will be other doses available, but at the moment, we just don't have the data for that.
- 41:38Nara: For that. Yeah. So it is not to advise. Stick to the
- 41:43Marcela: plan. Stick to to the the plan. Definitely.
- 41:47Nara: And if I, end on something that is I think is in all our minds, but we don't always talk about it, is self image. Yeah. So weight, fitness is so tied in to how we see ourselves. And, yeah, and the GLP-1s to to the to your point around sort of wanting to lose a couple of kilos perhaps, etcetera. Do you have a view on that on on self image with or without GLP-1s in the context of nutrition and, and to some degree in the context of what we were talking about when our one of our earlier podcasts, which is, you know, women around the perimenopause, etcetera.
- 42:24So, you know, self image and nutrition.
- 42:26Marcela: Yeah. Wow. That is huge. That's such a huge topic.
- 42:30Nara: We will talk about that to another one.
- 42:31Marcela: Oh, yes. We can talk about that forever because I think there are it's it's so real and it's so important and there are so many different levels and layers to it because there is obviously kind of that individual level. And, you know, for someone that has been living with overweight and obesity, the impacts on their body image, their confidence can be huge and
- 42:59Nara: It can be lifelong. It can be lifelong.
- 43:01Marcela: It can be absolutely life changing. So the amount of people that will tell me that before, they would absolutely not step their foot into a gym, for example, or an exercise class. But then the moments that they lose a little bit of weight, they feel a lot more comfortable, and that triggers a whole cascade of kind of healthier behaviors and positivity, which can be life changing. So there is there is that very kind of optimistic and positive side there, but then there is another darker side I find that I think we've all seen a lot of, like, people kind of in the media, and we've seen kind of in fashion, and everywhere people are kind of reducing their sizes. People are smaller.
- 43:45And I think there is no way to say that it's not happening. It is happening. So You see
- 43:49Nara: that you see that in celebrities.
- 43:50Marcela: You see
- 43:51Nara: that on social media.
- 43:51Marcela: We see that. And I think that is we are all influenced by that. Right? And and I do worry that suddenly this kind of very, very small bodies are becoming And normal I thought at some point that we had moved away from that. There was a whole movement around body positivity, which I think it's really kind of really important.
- 44:21Nara: Appreciating that we all come in different shapes and sizes. Yes,
- 44:24Marcela: yes, exactly. I think, you know, it's not promoting obesity, it's not promoting overweight, but I think it's acknowledging there are different sizes, different shapes.
- 44:33Nara: Naturally. Your natural state
- 44:35Marcela: Exactly. Between two people might look very similar. So, yeah, I do I do worry the effect that it will have kind of a population level in terms of body imaging. I think, obviously like for people they already suffer from eating disorders that can be kind of really, really scary and really triggering.
- 44:54Nara: So actually it would probably be fair to say as a closing statement that nutrition is absolutely at the center of healthy living and being intentional, holistic, and appreciative of that three sixty view of what your health looks like about exercise, holistic nutrition. So obviously, protein has taken a front seat in a lot of what we've talked about today. But appreciating fiber, essential minerals and nutrients
- 45:19Marcela: fats Yeah. Vitamins, minerals, all of it.
- 45:22Nara: Yeah. So actually Absolutely.
- 45:24Marcela: The way I see it's like that the the the the medicine is kind of is the front door. Yeah. You know? And then the nutrition, the exercise, the lifestyle, it's what you do once you are through that.
- 45:35Nara: Through that door. It's a It's that wraparound
- 45:37Marcela: Yeah.
- 45:38Nara: Holistic care. Fantastic. So, yeah, seek out Marcela or someone like you, as good as you, to look after your nutrition. Wonderful. Thank you so much, Marcela.
- 45:47Marcela: Thank you. You for having me. Thank you.